From health care to politics, here's who you need to know in Houston innovation this week. Courtesy photos

There's no summer slowdown in sight, as Houston's innovation world keeps turning. Texas Children's Hospital is amping up their attention to innovation — and so is the mayor. Meanwhile, a local software company just made a big hire. Here's what innovators you need to keep an eye on.

Myra Davis, senior vice president and chief information and innovation officer of Texas Children's Hospital

Myra Davis is responsible for Texas Children's Hospital's technology and innovation — two completely separate things, she says. Courtesy of TCH

Myra Davis wants you to realize that there's a difference between technology and innovation. As the chief information officer, she's been in charge of maintaining tech within the hospital system. However, her role has evolved to include innovation, which means thinking about what new elements TCH can bring in — or what existing elements can be improved or expanded. Read more about Davis and what TCH is up to.

Talin Bingham, CTO of Identity Automation

Talin Bingham has been named CTO of Houston-based Identity Automation. Courtesy of Identity Automation

The chief technology officer is a huge role when it comes to a software company's hierarchy. Houston-based Identity Automation just tasked Talin Bingham with the position. Bingham replaces co-founder Troy Moreland as CTO, and Moreland will support the company in an advisory capacity. Last summer, the company made a major acquisition and sees plenty of opportunities for growth. Read more about the new hire.

Mayor Sylvester Turner

Mayor Sylvester Turner gave his State of the City address on May 20. Natalie Harms/InnovationMap

Mayor Sylvester Turner and his team are innovators themselves, constantly coming up with new ideas to enhance and connect the city. The city's latest endeavor was announced last week at the Greater Houston Partnership's State of the City luncheon. Mayor Turner's idea is to have 50 corporations sponsor 50 Houston-area parks scattered across the city for five years. Up next is finding 49 more companies, since Scott McClelland of HEB offered up his company on the spot. Read the 5 things the mayor promised in the address.

Talin Bingham has been named CTO of Houston-based Identity Automation. Courtesy of Identity Automation

Houston software company hires new CTO after Q1 growth

Mover and shaker

Houston-based Identity Automation has named a new chief technology officer following growth last quarter.

Talin Bingham will replace co-founder Troy Moreland as CTO, and Moreland will support the company in an advisory capacity, according to a release.

"We are excited about the experience and wisdom that Talin brings to this role," says James Litton, CEO at Identity Automation, in the release.

"Talin is a seasoned CTO with an exceptional track record in on-time product delivery and implementation—both of which are essential to the Identity Automation 2.0 growth strategy. We are confident that his entrepreneurial spirit will help us achieve our vision of continued product evolution and rapid expansion across key markets."

Bingham has over 35 years of technical leadership — 25 of which has been in managerial roles. Prior to this appointment, he was the managing director of product and technology at Vista Consulting Group in Utah.

Identity Automation is the provider of RapidIdentity, which is a technology integration platform companies can use to accelerate the digital transformation process. The company has a global presence with tens of millions of identities in its system, which functions both on the premises and cloud resources.

Last summer, the company made its second acquisition — an enterprise single sign-on and virtual desktop platform called HealthCast Inc.

"Identity Automation has the most powerful and scalable platform in the identity management space, backed by a strong leadership team and the momentum of our recent success." Bingham says in the release.

"I'm excited to have a hand in the company's direction during such a pivotal time, ensuring we maximize the quality and delivery of engineering and do so as a cohesive, company-wide effort that make it possible to meet our full potential for growth."

James Litton Discusses Cybersecuritywww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.